Arcutis Biotherapeutics had its Relative Strength (RS) Rating upgraded from 77 to 82 Friday.
Risk Management In The Stock Market: How Much Money To Invest Now
IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks holds up against all the other stocks in our database.
History shows that the best stocks typically have an 80 or higher RS Rating in the early stages of their moves.
Arcutis Biotherapeutics is working on a consolidation with a 17.75 buy point. See if the stock can clear the breakout price in heavy volume.
The company reported 0% earnings growth in its most recent report, while sales growth came in at 33%.
Arcutis Biotherapeutics holds the No. 77 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, Catalyst Pharmaceuticals and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
